Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma network).
diffuse large B-cell lymphoma
efficacy
pixantrone
safety
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
13
01
2022
received:
30
11
2021
accepted:
17
01
2022
pubmed:
21
1
2022
medline:
23
4
2022
entrez:
20
1
2022
Statut:
ppublish
Résumé
Pixantrone is a novel aza-anthracenedione with antineoplastic activity, currently approved for multiply relapsed/refractory diffuse large B-cell lymphoma (DLBCL), even if real-life data are limited. We investigated pixantrone efficacy and safety in clinical practice, as 3 Pixantrone was administered as 3 In this real-life setting, pixantrone demonstrated appreciable efficacy in a population with poor prognosis; in a small proportion of cases, it can be associated with long-term remission.
Substances chimiques
Isoquinolines
0
Rituximab
4F4X42SYQ6
pixantrone
F5SXN2KNMR
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-390Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v116-v125.
Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
Ambrosio MR, Lazzi S, Bello GL, et al. MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. Haematologica. 2019;104:e25-e28.
Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL-2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31:37-42.
Kühnl A, Cunningham D, Counsell N, et al. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol. 2017;28:1540-1546.
Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) group. Lancet Oncol. 2011;12:1013-1022.
Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11:9.
Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182:633-643.
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800-1808.
Mordente A, Meucci E, Silvestrini A, et al. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009;16:1656-1672.
Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622-1627.
Hong JY, Yoon DH, Suh C, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Ann Hematol. 2018;97:1437-1443.
Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155-165.
Maerevoet M, Zijlstra JM, Follows G, et al. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. J Hematol Oncol. 2021;14:111.
Locke FL, Go WY, Neelapu SS. Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. JAMA Oncol. 2020;6:281-290.
Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007;25:187-195.
Boyle EM, Morschhauser F. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Saf. 2015;14:601-607.
Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13:696-706.
Pettengell R, Sebban C, Zinzani PL, et al. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016;174:692-699.
Pettengell R, Coiffier B, Egorov A, et al. Long-term response and remission with pixantrone in patients with relapsed or refractory aggressive non-hodgkin lymphoma: post-hoc analysis of the multicenter, open-label, randomized PIX301 trial. Clin Drug Investig. 2018;38:527-533.
Eyre TA, Linton KM, Rohman P, et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma. Br J Haematol. 2016;173:896-904.
Novakovic A, Boltezar L, Novakovic BJ. Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma. Oncol Lett. 2020;19:2028-2034.
Sancho JM, Navarro B, Soler Campos JA, et al. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Eur J Haematol. 2020;104:499-508.
Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11:462-466.
Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014;93:403-409.
Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5:2707-2716.
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-2544.
Zinzani PL, Bregni M, Spione M, et al. Effectiveness and safety of pixantrone for the treatment of relapsed or refractory diffuse large B-Cell lymphoma in every-day clinical practice: the italian cohort of the PIXA registry. Acta Haematol. 2021;144:259-263.
Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the fondazione italiana linfomi. J Clin Oncol. 2021;39:1214-1222.
Appio L, Landoni C, La Targia M, et al. Single-agent pixantrone as a bridge to autologous stem cell transplantation in a patient with refractory diffuse large B-cell lymphoma. Chemotherapy. 2017;62:187-191.
Malaspina F, Pellegrini C, Casadei B, et al. Impressive response to pixantrone after allogeneic transplant in a multiple relapsed diffuse large B-cell lymphoma. Acta Haematol. 2017;137:191-194.
Pettengell R, Długosz-Danecka M, Andorsky D, et al. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Br J Haematol. 2020;188:240-248.
Barrenetxea Lekue C, Grasso Cicala S, Leppä S, et al. Pixantrone beyond monotherapy: a review. Ann Hematol. 2019;98:2025-2033.